Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 10;219(10):e201911120. doi: 10.1083/jcb.201911120

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Khalil et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure S6. — Role of ADORA1 in preclinical spontaneous metastasis and prognostic relevance in clinical samples. (a) Detection of ADORA1 in normal ducts within clinical samples using multispectral microscopy. (b) Frequency of ADORA1-positive cancer cells with collective invasion patterns in breast lesions. Data represent the fibrous and adipose tissue from individual patients. (c) Overviews of lung sections isolated from DMSO and PSB36 (30 mg/kg) treated mice, stained for cytokeratin-8. Insets and arrowheads depict macro- and micrometastases. (d) Average number of micro- and macrometastases normalized per lung section. Data represent a total of 135–145 lung sections from three independent mice per group. (e) Relative frequency of micro- or macrometastases per treatment group: DMSO: 39 micrometastases, 59 macrometastases, 98 total; PSB36: 39 micrometastases, 91 macrometastases, 130 in total. Data show the mean percentages and SD from three mice. P value, two-tailed unpaired Mann–Whitney test. (f and g) Kaplan–Meier survival analysis predicting RFS in (f) basal-type breast cancer patients. (g) Correlation of ADORA1 or combined ADORA1 and Cx43 expression in clinical samples. Classification was based on tumor grade and molecular subtype (Györffy et al., 2010). Bold and underlined values show the positive (black) or inverse (green) association with ADORA1/Cx43 expression. (f and g) P values, log-rank test. Scale bars: 100 µm (a), 50 µm (a and c, inset), 1,000 µm (c, overview).